NIAGARA
08 Dec 2020
NIAGARA
NCT03732677
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
AstraZeneca
Cancer Type | Bladder |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 years and older |
Sex | Both |
Tumour Stream | muscle-invasive bladder cancer |
Cancer Stage | All stages |
Anticipated Start Date | 2018-11-16 |
Anticipated End Date | 2025-12-18 |
Hospitalt | Lyell McEwin Hospital |
---|---|
Clinical Trial Coordinator | Andy Phay |
andy.phay@sa.gov.au | |
Phone | 08 8282 0833 |
Principal Investigator | Dr Christopher Hocking |
Recruitment Status | Recruiting |